ArticleObesity surgery2026
Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGLP-1-RAs and metabolic bariatric surgery (MBS) both improve outcomes in obesity. This study compares the effectiveness and safety of early GLP-1 initiation (≥ 3 months before) versus delayed initiation (≥ 1 month after) in adults undergoing MBS.
methodsRetrospective cohort study using TriNetX. Adults with BMI > 30 were classified into GLP-1 RA after MBS, GLP-1 before MBS, and MBS-only cohorts. We performed 1:1 propensity score matching to compare each GLP-1 RA strategy to MBS only. Outcomes included mortality, CKD, 5-point MACE, osteoporosis, micronutrient deficiencies, SBO, internal hernia, and cholelithiasis and were assessed within 1 year. Cox proportional hazards models were used, excluding patients with pre-existing baseline conditions.
resultsGLP-1 after MBS reduced the risk of death by 88% (HR 0.12, 95% CI 0.08-0.18) and 5-point MACE by 16% (HR 0.84, 95% CI 0.71-0.98) compared with MBS alone. In contrast, initiating GLP-1 RA before MBS reduced mortality by 80% (HR 0.20, 95% CI 0.14-0.30) only. GLP-1 after MBS also lowered the risk of micronutrient deficiency by 10% (HR 0.90, 95% CI 0.83-0.97), whereas GLP-1 RA before MBS increased this risk by 18% (HR 1.18, 95% CI 1.08-1.28). GLP-1 RA after MBS reduced the risk of SBO by 65% (HR 0.35, 95% CI 0.28-0.44), compared with a 39% reduction for GLP-1 RA before MBS (HR 0.61, 95% CI 0.49-0.76). GLP-1 RA use after MBS was associated with lower risks of internal hernia (HR 0.59, 95% CI 0.42-0.82) and cholelithiasis (HR 0.77, 95% CI 0.66-0.90), whereas GLP-1 RA before MBS did not show a significant difference for either outcome.
conclusionInitiating GLP-1 RA therapy after MBS appears to provide the most favorable balance of survival, cardiometabolic outcomes, and postoperative complications. These findings, particularly those related to mortality, should be interpreted with caution given the observational design and immortal time bias.
Indexed as
Identifiers
42471527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.